Chong Kun Dang, 44,897 Shares Net Sold by Foreigners in Last 5 Days... Stock Price at 158,500 KRW (-18.72%)

As of 10:30 AM on the 18th, Chong Kun Dang is trading at 158,500 KRW, down 18.72% from the previous day. The trading volume is 757,689 shares, which is about 31.55% of the previous day's volume. Chong Kun Dang is known as a leading pharmaceutical company in the industry, focusing on therapeutics.

On March 15, researcher Oh Byung-yong from Hanyang Securities noted, "Attention should be paid to ‘Nafamostat’ (product name Napabeltan), which Chong Kun Dang is developing as a COVID-19 treatment. The Korea Pasteur Institute announced that ‘Nafamostat’ is 600 times more effective than Remdesivir at the cellular level, generating high expectations. Approval is expected in April. The market approval of a COVID-19 treatment can act as significant momentum in the stock market. Although there are many candidate substances for COVID-19 treatments, if one were to pick the most promising, it would be Nafamostat." He set Chong Kun Dang’s target price at 198,000 KRW.

Over the past five days, individual investors have net purchased 34,549 shares of Chong Kun Dang, while foreigners and institutions have net sold 44,897 shares and net purchased 12,582 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.